An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer

Oncology

Volumn 55, Issue 1, 1997, Pages 10-15

  Pectasides, D ^a   Varthalitis, J ^a   Kostopoulou, M ^a   Mylonakis, A ^a   Triantaphyllis, D ^a   Papadopoulou, M ^a   Dimitriadis, M ^a   Athanassiou, A ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

Interferon; Interleukin 2; Renal cell cancer; Vinblastine

Indexed keywords

ALPHA2B INTERFERON; INTERLEUKIN 2; LIVER ENZYME; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; EOSINOPHILIA; FEMALE; FEVER; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INFLAMMATION; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALAISE; MALE; METASTASIS; NAUSEA; OUTPATIENT; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING; AMBULATORY CARE; DRUG ADMINISTRATION; KIDNEY CARCINOMA; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VINBLASTINE;

EID: 0031600196     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011829     Document Type: Article

References (32)

1. Hrushesky WJ, Murphy GP: Current status of the therapy of advanced renal carcinoma. J Surg Oncol 1977; 9: 277-288.
2. Torti FM: Treatment of metastatic renal cell carcinoma. Recent results. Cancer Res 1983; 85: 123-142.
3. Harris DT: Hormonal therapy and chemotherapy of renal cell carcinoma. Semin Oncol 1984; 10: 422-430.
4. Krown SE: Therapeutic options in renal cell carcinoma. Semin Oncol 1987; 12: 13-17.
5. Muss HB: Interferon therapy for renal cell carcinoma. Semin Oncol 1987; 14: 36-42.
6. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987; 316: 889-897.
7. Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MS, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1988; 108: 518-523.
8. Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parillo JE, Rosenberg SA: Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989; 7: 7-20.
9. Atzpodien J, Korfer A, Evers P, Franks CR, Knuver-Hopf J, Lopez-Hanninen E, Fischer M, Mohr H, Dallmann I. Hadam M: Low dose subcutaneous recombinant interleukin-2 in advanced human malignancy: A phase II outpatient study. Mol Biother 1990; 2: 18-26.
10. Aapro MS, Alberts DS, Salmon SE: Interactions of human leucocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumours in clonogenic assay. Cancer Chemother Pharmacol 1983; 10: 161-168.
11. Fossa SD, De Garis ST, Heier MS, Flokkman A, Lien HH, Salveson A, Moe B: Recombinant interferon alpha-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 1986; 57: 1700-1704.
12. Kellokumpu-Lehtinen P, Nordman E: Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: A clinical phase I-II study. J Biol Response Mod 1990; 9: 439-444.
13. Bergerat JP, Herbrecht R, Dufour P, Jacqmin D, Bollack C, Prevot G, Bailly G, de Garis S, Juraschek F, Oberling F: Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer. Cancer 1988; 62: 2320-2324.
14. Cameron RB, MacIntosh JK, Rosenberg SA: Synergistic antitumour effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α -interferon in the treatment of established murine hepatic metastasis. Cancer Res 1988; 48: 5810-5817.
15. Brunda MJ, Bellantoni D, Sulich V: In vivo antitumour activity of combinations of interferon-α and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987; 40: 365-371.
16. Iigo M, Sakurai J, Tamura T: In vivo antitumour activity of multiple injections or recombinant interleukin-2 alone and in combination with three different types of recombinant interferon on various syngeneic murine tumours. Cancer Res 1988; 48: 260-264.
17. Kuebler JP, Whitehead RP, Ward DL, Hemstreet GP, Bradley EE: Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells. J Urol 1993; 150: 814-820.
18. Sella A, Zukiwski E, Robinson R, Kilbourn J, Ellerhorst J, Amato R, Logothetis C: Interleukin-2 (IL-2) with interferon-α (IFN-α ) and 5-fluorouracil (5-FU) in patients (pts) with metastatic renal celler cancer. Proc ASCO 1994; 13: 237.
19. Atzpodien J, Kirchner H, Hannien EL, Deckert M, Fenner M, Poliwoda H: Interleukin-2 in combination with interferon-α and 5-fluoro-uracil for metastatic renal cell cancer. Eur J Cancer 1993; 29(suppl 5): 56-58.
20. Hirsch M, Lipton A, Harvey H, Givant E, Hopper K, Jones G, Zaffren J, Levitt D: Phase I study of IL-2 and IFN-a-2a as outpatient therapy for patients with advanced malignancy. J Clin Oncol 1990; 8: 1657-1663.
21. Figlin RA, de Kernion JB, Mukamel E, Palleroni AV, Itri LM, Sarna GP: Recombinant Interferon α -2a in metastatic renal cell carcinoma. Assessment of antitumor activity and antiinterferon antibody formation. J Clin Oncol 1988; 6: 1604-1610.
22. Smith KA: Interleukin-2. Inception, impact, and implications. Science 1988; 240: 1169-1176.
23. Rosenberg SA, Schwarz SL, Spiess PJ: Combination immunotherapy for cancer: Synergistic antitumor interactions of interleukin-2, α -interferon and tumor infiltration lymphocytes. J Natl Cancer Inst 1988; 80: 1393-1397.
24. Brunda MJ, Tarnowski D, Davatelis V: Interaction of recombinant interferons with recombinant interleukin-2. Differential effects on natural killer cell activity and interleukin-2 activated killer cells. Int J Cancer 1986; 37: 787-793.
25. Rosenberg SA, Lotze MT, Yang JC, Linchan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg RM, White DE: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7: 1863-1874.
26. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H: Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies. Lancet 1990; 335: 1509-1512.
27. Atzpodien J, Korfer A, Menzel T, Poliwoda H, Kirchner H: Home therapy using recombinant human interleukin-2 and interferon-α -2b in patients with metastatic renal cell carcinoma (abstract). Proc ASCO 1991; 10: 177.
28. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alpha-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 1993; 11: 1809-1816.
29. Selli C, Hinshaw WM, Woodard BH, Paulson DF: Stratification of risk factors in renal cell carcinoma. Cancer 1983; 52: 899-903.
30. Meldeiros LJ, Gelb AB, Weiss LM: Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 1988; 61: 1639-1651.
31. Meldeiros LJ, Weiss LM: Renal adenocarcinoma; in Elbe JN (ed): Tumours and Tumour Like Conditions of the Kidneys and Ureters. New York, Churchill Livingstone, 1990, pp 35-70.
32. Neidhart JA, Anderson SA, Harris JE, Rinehart J, Laszlo J, Dexeus FH, Einhorn LH, Trump DL, Benedetto PW, Tuttle RL, Smalley RV: Vinblastine fails to improve response of renal cancer to interferon alpha-nl. High response rate in patients with pulmonary metastases. J Clin Oncol 1991; 9: 832-837.